JP2017534652A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017534652A5 JP2017534652A5 JP2017525360A JP2017525360A JP2017534652A5 JP 2017534652 A5 JP2017534652 A5 JP 2017534652A5 JP 2017525360 A JP2017525360 A JP 2017525360A JP 2017525360 A JP2017525360 A JP 2017525360A JP 2017534652 A5 JP2017534652 A5 JP 2017534652A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- composition according
- leukemia
- pharmaceutically acceptable
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 34
- 150000001875 compounds Chemical class 0.000 claims description 28
- 208000032839 leukemia Diseases 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 6
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 239000008299 semisolid dosage form Substances 0.000 claims description 4
- 239000007909 solid dosage form Substances 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 238000011476 stem cell transplantation Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 9
- 125000001309 chloro group Chemical group Cl* 0.000 description 16
- 125000001153 fluoro group Chemical group F* 0.000 description 16
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 8
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 7
- 125000001246 bromo group Chemical group Br* 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- -1 methoxy, ethoxy Chemical group 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 0 CN(c1cccc(*)c1C(O)=C1C(N(*)c2ccccc2)=O)C1=O Chemical compound CN(c1cccc(*)c1C(O)=C1C(N(*)c2ccccc2)=O)C1=O 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14193776.3 | 2014-11-19 | ||
| EP14193776 | 2014-11-19 | ||
| PCT/EP2015/075769 WO2016078921A1 (en) | 2014-11-19 | 2015-11-05 | Quinoline carboxamides for use in the treatment of leukemia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017534652A JP2017534652A (ja) | 2017-11-24 |
| JP2017534652A5 true JP2017534652A5 (2) | 2018-12-06 |
| JP6715833B2 JP6715833B2 (ja) | 2020-07-01 |
Family
ID=51951635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525360A Active JP6715833B2 (ja) | 2014-11-19 | 2015-11-05 | 白血病の治療に使用するためのキノリンカルボキサミド |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10300053B2 (2) |
| EP (1) | EP3180005B1 (2) |
| JP (1) | JP6715833B2 (2) |
| KR (1) | KR102525805B1 (2) |
| CN (1) | CN107072989B (2) |
| AU (1) | AU2015348778B2 (2) |
| BR (1) | BR112017009854B1 (2) |
| CA (1) | CA2967112C (2) |
| EA (1) | EA031643B1 (2) |
| ES (1) | ES2663836T3 (2) |
| IL (1) | IL252174B (2) |
| MX (1) | MX379401B (2) |
| NZ (1) | NZ732704A (2) |
| PL (1) | PL3180005T3 (2) |
| WO (1) | WO2016078921A1 (2) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL295780A (en) | 2020-03-03 | 2022-10-01 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy |
| AU2021313388A1 (en) | 2020-07-23 | 2023-01-19 | Erasmus University Medical Center Rotterdam (Erasmus Mc) | S100 proteins as novel therapeutic targets in myeloproliferative neoplasms |
| CN116887844A (zh) * | 2021-01-18 | 2023-10-13 | 活跃生物技术有限公司 | 用于治疗骨髓增生异常综合征的他喹莫德或其药学上可接受的盐 |
| KR20230133317A (ko) | 2021-01-18 | 2023-09-19 | 액티브 바이오테크 에이비 | 골수이형성 증후군의 치료에 이용하기 위한 타스퀴니모드또는 이의 약제학적으로 허용가능한 염 |
| KR20240012436A (ko) | 2021-05-25 | 2024-01-29 | 액티브 바이오테크 에이비 | 복수의 타스퀴니모드 입자 및 그 용도 |
| WO2023275248A1 (en) | 2021-07-02 | 2023-01-05 | Active Biotech Ab | A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE0002320D0 (sv) * | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| PT2590949E (pt) | 2010-07-09 | 2016-03-07 | Active Biotech Ab | Método para o fabrico de quinolina-3-carboxamidas |
| EP2537517A1 (en) | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| WO2015095833A1 (en) | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Treatment of hematologic cancers |
-
2015
- 2015-11-05 JP JP2017525360A patent/JP6715833B2/ja active Active
- 2015-11-05 EA EA201791099A patent/EA031643B1/ru not_active IP Right Cessation
- 2015-11-05 BR BR112017009854-7A patent/BR112017009854B1/pt active IP Right Grant
- 2015-11-05 AU AU2015348778A patent/AU2015348778B2/en active Active
- 2015-11-05 CN CN201580062750.4A patent/CN107072989B/zh active Active
- 2015-11-05 PL PL15790143T patent/PL3180005T3/pl unknown
- 2015-11-05 NZ NZ732704A patent/NZ732704A/en unknown
- 2015-11-05 MX MX2017006110A patent/MX379401B/es unknown
- 2015-11-05 CA CA2967112A patent/CA2967112C/en active Active
- 2015-11-05 WO PCT/EP2015/075769 patent/WO2016078921A1/en not_active Ceased
- 2015-11-05 KR KR1020177015989A patent/KR102525805B1/ko active Active
- 2015-11-05 ES ES15790143.0T patent/ES2663836T3/es active Active
- 2015-11-05 EP EP15790143.0A patent/EP3180005B1/en active Active
- 2015-11-05 US US15/525,086 patent/US10300053B2/en active Active
-
2017
- 2017-05-09 IL IL252174A patent/IL252174B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017534652A5 (2) | ||
| JP2015511609A5 (2) | ||
| JP2016528301A5 (2) | ||
| JP2015505296A5 (2) | ||
| JP2016534063A5 (2) | ||
| JP2019524883A5 (2) | ||
| JP2013501731A5 (2) | ||
| JP2015511638A5 (2) | ||
| JP2016525121A5 (2) | ||
| JP2016520618A5 (2) | ||
| JP2019515908A5 (2) | ||
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| JP2015524444A5 (2) | ||
| JP2015529234A5 (2) | ||
| JP2017506624A5 (2) | ||
| JP2017528473A5 (2) | ||
| JP2015522033A5 (2) | ||
| NZ625592A (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| JP2019516739A5 (2) | ||
| JP2019520344A5 (2) | ||
| JP2016522254A5 (2) | ||
| CN107108510B (zh) | 用于治疗多发性骨髓瘤的喹啉甲酰胺 | |
| JP2015517523A5 (2) | ||
| CN107072989B (zh) | 用于治疗白血病的喹啉甲酰胺 | |
| JP2013523740A5 (2) |